Contineum reports Q1 net loss $14.5M; cash $246.3M through mid-2029

Contineum Therapeutics, Inc.

2026-Q1 EPS reported -$0.39

Cash, cash equivalents and marketable securities of $246.3M as of March 31, 2026; runway through mid-2029.
Net loss of $14.5M vs $16.0M in Q1 2025; R&D expenses down 15% to $11.6M.
Positive topline Phase 1b data for PIPE-791 in chronic pain (April 30, 2026); safety met and numeric pain improvement.
Initiated global Phase 2 PROPEL-IPF trial for PIPE-791 in IPF; target 324 patients; enrollment ongoing.
Johnson & Johnson Phase 2 Moonlight-1 trial of PIPE-307 in MDD recruiting 124 participants; completion expected June 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Contineum Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $14.5 million.

Period: first quarter ended March 31, 2026
Net income: Net loss was $14.5 million
Result: reported results

Exact text from the filing

million, a 20 percent increase from the first quarter of 2025. The increase was primarily driven by higher stock-based compensation and employee-related costs. • Net loss was $14.5 million for the three months ended March 31, 2026, as compared to $16.0 million for the first quarter of 2025.

View on SEC.gov

Browse all earnings releases →

Contineum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-030522

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.